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Protein citrullination is a calcium-driven post-translational modification proposed to play 
a causative role in the neurodegenerative disorders of Alzheimer’s disease, multiple 
sclerosis (MS), and prion disease. Citrullination can result in the formation of antigenic 
epitopes that underlie pathogenic autoimmune responses. This phenomenon, which 
is best understood in rheumatoid arthritis, may play a role in the chronic dysfunction 
following traumatic brain injury (TBI). Despite substantial evidence of aberrations in cal-
cium signaling following TBI, there is little understanding of how TBI alters citrullination 
in the brain. The present investigation addressed this gap by examining the effects of 
TBI on the distribution of protein citrullination and on the specific cell types involved. 
Immunofluorescence revealed that controlled cortical impact in rats profoundly up- 
regulated protein citrullination in the cerebral cortex, external capsule, and hippocampus. 
This response was exclusively seen in astrocytes; no such effects were observed on the 
status of protein citrullination in neurons, oligodendrocytes or microglia. Further, pro-
teomic analyses demonstrated that the effects of TBI on citrullination were confined to a 
relatively small subset of neural proteins. Proteins most notably affected were those also 
reported to be citrullinated in other disorders, including prion disease and MS. In vivo 
findings were extended in an in vitro model of simulated TBI employing normal human 
astrocytes. Pharmacologically induced calcium excitotoxicity was shown to activate the 
citrullination and breakdown of glial fibrillary acidic protein, producing a novel candidate 
TBI biomarker and potential target for autoimmune recognition. In summary, these 
findings demonstrate that the effects of TBI on protein citrullination are selective with 
respect to brain region, cell type, and proteins modified, and may contribute to a role for 
autoimmune dysfunction in chronic pathology following TBI.
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introduction
Traumatic brain injury (TBI) is a major cause of injury and death 
in the US, with over 1.7 million TBIs occurring annually and at 
least 5.3 million Americans currently living with ongoing dis-
ability (1). Traumatic brain injuries in civilians are largely due 
to automobile accidents as well as falls, sports, and firearms (2). 
Military populations are at disproportionately elevated risk for 
blast-related TBI due to the devastating effects of improvised 
explosive devices (3). While there is a very large body of infor-
mation on causes and global consequences of TBI, much less is 
known about the mechanisms underlying long-term pathology.
The long-term consequences of TBI can be complex, and often 
result in progressive cognitive and behavioral changes. Studies 
have indicated that anywhere from 10 to 50% of individuals 
with TBI suffer from persistent symptoms following injury (4), 
including attention deficits and short-term memory loss (1). This 
long-term dysfunction follows in the wake of two main injury 
phases: (1) the primary injury, caused by the immediate forces of 
the trauma (2, 5); and (2) the subsequent secondary injury, which 
presents as a constellation of dysfunctional molecular processes 
including impaired metabolism, free radical production, inflam-
mation, and glutamate excitotoxicity (1). At present, it is not well 
understood how these various dysfunctional processes following 
acute injury can lead to progressive, chronic pathology after TBI. 
This ongoing pathology includes deficits in executive function, 
attention, processing speed, learning and memory formation and 
well as behavioral changes in both emotion and affect (1, 4).
A hallmark mechanism of secondary injury following TBI is 
prolonged imbalance in cellular calcium homeostasis, resulting 
in excitotoxic calcium overload (6–8). The downstream effects 
of cellular calcium toxicity have been examined closely in regard 
to mitochondrial dysfunction and oxidative stress. However, lit-
tle attention has been given to the role of TBI-induced calcium 
overload in the activation of peptidylarginine deiminase (PAD) 
enzymes. This family of calcium-dependent enzymes catalyzes the 
post-translational modification of citrullination, resulting in the 
conversion of intrapeptidyl arginine residues to citrulline residues. 
In addition to altering both the normal structure and function of 
proteins, citrullination generates “altered-self ” epitopes that may 
be antigenic, prompting autoimmune responses against previously 
benign proteins (9, 10). Altered calcium homeostasis accom-
panied by protein citrullination has been implicated in several 
neurodegenerative disorders, including Alzheimer’s disease (11), 
temporal lobe epilepsy (12), glaucoma (13), rheumatoid arthritis 
(14), and multiple sclerosis (MS) (15). In MS, the citrullination 
of myelin basic protein (MBP) limits the ability of this protein to 
appropriately associate with lipids (16), which in turn contributes 
to demyelination by destabilizing sheath structure (17). It has 
been proposed that the dysfunctional effects of citrullination on 
myelin sheath structure play a major role in the development of 
MS (16). Furthermore, citrullinated proteins are also observed 
within the extracellular plaques seen in post-mortem brains 
affected by Alzheimer’s disease, suggesting a functional role for 
this modification in neurodegenerative pathology.
At present, understanding of the specific proteins modified 
by citrullination is very limited outside the field of immunology, 
where the antigenic properties of abnormal citrullination are 
studied largely within the context of rheumatoid arthritis. 
Additionally, there is no data available regarding the regional and 
cellular specificity of protein citrullination in neural tissue fol-
lowing TBI. Here, we identify the regions and cell types most sus-
ceptible to protein citrullination following TBI, and also identify 
a subset of neural proteins that are preferentially citrullinated in 
response to injury. Furthermore, we present the development of 
an in vitro model for simulating TBI through astrocytic calcium 
excitotoxicity, and identify a citrullinated breakdown product of 
glial fibrillary acidic protein (GFAP). Until now, citrullination has 
been primarily associated with chronic, progressive autoimmune 
and neural disorders. The present findings indicate that protein 
citrullination is a feature of TBI that may contribute to the long-
term pathogenic mechanisms following acute injury, including 
those that involve the adaptive immune system.
Materials and Methods
controlled cortical impact
Controlled cortical impact (CCI) was conducted as described in 
Lazarus et al. (18). Briefly, adult male and female Sprague-Dawley 
rats (Charles River Laboratories, Morrisville, NC, USA) were 
anesthetized, then subjected to unilateral CCI over the left hemi-
sphere administered through a Impact One stereotaxic impactor 
(Leica Microsystems, Buffalo Grove, IL, USA), which delivered 
a 3 mm flat-tipped impactor at 20° to a depth of 2 mm at 5 m/s 
with a 500 ms dwell time at −3.8 mm bregma in males/−3.0 mm 
bregma in females. Naïve animals received no anesthesia or CCI 
treatment. Animals were euthanized 5 days following injury. All 
animal handling procedures were performed in compliance with 
guidelines from the National Research Council for the ethical 
handling of laboratory animals, as approved by the Institutional 
Animal Care and Use Committee of USUHS (IACUC Protocol 
APG 12-827, Bethesda, MD, USA).
immunohistochemistry
Tissue Collection and Preparation
Tissue was collected and prepared as described previously (18). 
Briefly, euthanized animals underwent transcardial perfusion 
[phosphate-buffered saline (PBS) followed by 4% paraformal-
dehyde] after which brains were removed for storage overnight 
at 4°C in 4% paraformaldehyde and then equilibration in a 
30% sucrose solution (2  days, 4°C). Brains were sectioned 
coronally (20 μm) across the breadth of the lesion site (2.5 mm 
rostral to 2.5 mm caudal) with a Leica CM1900 cryostat (Leica 
Microsystems), and sections were then mounted on slides and 
stored at −80°C. The following groups of gender/conditions were 
prepared for immunohistochemical analysis: n =  11 male rats, 
CCI; n = 8 male rats, naïve control; n = 10 female rats, CCI; and 
n = 7 female rats, naïve control.
Detection of Cell-Specific Citrullination
The region and cell-specific effects of CCI on protein citrullina-
tion were determined using a mouse monoclonal anti-citrulline 
antibody (mAb 6B3, IgG2b) (19). The antibody was purified 
from expression medium by Protein A affinity chromatography 
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(HiTrap Protein A HP column (17-0403-01; GE Healthcare, 
Buckinghamshire, UK) on a GE ÄKTA FPLC fast protein liquid 
chromatography instrument (FPLC; 18-1900-26; GE Healthcare), 
aliquoted for single use and stored at −80°C.
Immunodetection of citrullinated proteins was performed 
as follows. Brain sections were incubated at 4°C overnight with 
125 μl of 1:1000 mouse anti-citrulline 6B3 antibody in 0.3% Triton 
X-100/PBS, with 1:100 normal donkey serum (NDS) as a block-
ing agent (16 sections/animal). Co-localization experiments were 
performed by co-incubating these sections with mAb 6B3 and 
either (1) goat anti-GFAP (1:1000; ab53554; Abcam, Cambridge, 
England) (astrocytes); (2) goat anti-ionized calcium-binding 
adapter molecule (Iba1; 1:500; ab5076; Abcam) (microglia); (3) 
rabbit anti-neuronal nuclei (NeuN; 1:500; ab104225; Abcam) 
(neurons); or (4) rabbit anti-MBP (1:1000; ab40390; Abcam) 
(oligodendroglia). Slides were washed five times with 0.2% 
Triton X-100/PBS and then incubated for 30  min with 125 μl 
of secondary antibody solution: 1:100 donkey anti-mouse IgG 
(H +  L), conjugated to green-fluorescent Alexa Fluor 488 dye 
(A-21202; Invitrogen, Waltham, MA, USA); and either 1:100 
donkey anti-goat, conjugated to red-fluorescent Alexa Fluor 594 
(A-11058; Invitrogen) or 1:100 donkey anti-rabbit, conjugated 
to red-fluorescent Alexa Fluor 594 (A-21207; Invitrogen). The 
sections were washed five times with 0.2% Triton X-100/PBS and 
one time with 1× PBS (5 m) and then visualized with an Olympus 
BX61 fluorescent motorized system microscope (Olympus, 
Shinjuku, Tokyo, Japan) using iVision-Mac software (BioVision 
Technologies, Exton, PA, USA).
Preadsorption Control
Specificity of the mAb 6B3 anti-citrulline antibody in immu-
nofluorescence was confirmed through immunoneutralization 
using a mixture of citrullinated protein molecular weight 
standards (trypsinogen, glyceraldehyde 3-phosphate dehydro-
genase, bovine albumin, trypsin inhibitor, alpha-lactalbumin, 
carbonic anhydrase, and egg albumin) prepared in-house via 
10  h incubation at 37°C with active PAD enzyme cocktail 
(0.5  μg/μl; P312-37C-25; SignalChem, Richmond, British 
Columbia, Canada) in Tris buffer (50 mM Tris HCl, pH 7.4); 
5  mM CaCl2; and 0.73  mM dithiothreitol (DTT) (Sigma-
Aldrich, St. Louis, MO, USA). Concurrently, a control sample 
was prepared in an identical manner, without the addition of 
the PAD enzyme cocktail.
identification of citrullinated Protein species in 
injured rat Brain
Tissue Collection and Preparation
Brains were collected, snap-frozen with powdered dry ice, and 
stored at −80°C until use. Brains were thawed on wet ice and 
then hand dissected to produce blocks of tissue encompassing the 
lesion site and the surrounding tissue shown by immunohisto-
chemistry to have increased protein citrullination following CCI. 
The equivalent region from naïve animals (control tissue) was 
similarly collected. Tissue blocks were homogenized in 5 volumes/
tissue weight extraction solution, consisting of: 7.7 M urea; 2.2 M 
thiourea; and 4.4% CHAPS; also containing 1× complete protease 
inhibitor mix (Roche). Samples were clarified by centrifugation 
(20,000 × g, 10 min, 4°C), and resulting  supernatants were frac-
tionated by 2-dimensional electrophoresis (2-DE).
Fluid-Phase Isoelectric Focusing
Treatment group pools (control and injured tissue) were prepared 
(N = 4/pool) and fractionated by fluid-phase isoelectric focus-
ing (F-IEF). Briefly, 200 μl aliquots of each pool were diluted 
up to 2.865  ml in IEF running solution (7.7  M urea; 2.2  M 
thiourea; 4.4% CHAPS; ampholytes (150 μl, pH 3–10; ZM0021, 
Invitrogen); DTT (50 μl, 2  M); and bromophenol blue (10 μl, 
10 mg/ml). Samples were loaded into the ZOOM IEF Fractionator 
(ZMF10002; Invitrogen) and focused according to the following 
conditions: (1) 100 V, 1.2 mA, 0 W (15 min); (2) 200 V, 2.0 mA, 
0 W (1 h); (3) 400 V, 2.0 mA, 1 W (1 h); and (4) 600 V, 1.5 mA, 1 W 
(1 h) resulting in fractions of proteins within the following five pI 
ranges: 3.0–4.6; 4.6–5.4; 5.4–6.2; 6.2–7.0; and 7.0–9.1.
Molecular Weight Fractionation
Proteins in each of the F-IEF fractionations were further resolved 
by molecular weight fractionation using conventional one-
dimensional gel electrophoresis. Samples were combined with an 
equal volume of 4× reducing loading buffer (Novex NuPAGE LDS 
sample buffer; 50 mM DTT; Invitrogen), heated at 70°C (20 min) 
and then fractionated (10 μl/well) using NuPAGE 4–12% Bis–Tris 
gels (Novex, Invitrogen), using 1× MES (2-[N-morpholino]
ethanesulfonic acid) running buffer (Novex, Invitrogen). Proteins 
were transferred to nitrocellulose blots using an iBlot transfer 
apparatus and gel transfer stacks (Nitrocellulose Mini; 1B301002, 
Invitrogen).
Immunoblotting
Blots were blocked with 5% instant non-fat dry milk/Tris-
buffered saline/Tween 20 (TBS-T) (1 h, room temperature) and 
then incubated with the 6B3 primary antibody (1:300 in TBS-T; 
mAb stock =  1.79  mg/ml) for 1  h at room temperature, then 
4°C overnight. Following equilibration to room temperature 
(30  min), membranes were washed in TBS-T (five times over 
60  min), incubated with secondary antibody, horseradish 
peroxidase-labeled, goat anti-mouse IgG (1:2500 in 5% TBS-
T; 31430, Thermo Scientific) for 2  h at room temperature and 
then visualized by enhanced chemiluminescence (ECL) (Novex 
ECL HRP Chemiluminescent Substrate Reagent Kit; WP20005, 
Invitrogen) using the FUJI LAS 3000 Imager (Fujifilm, Minato, 
Tokyo, Japan). Images collected were analyzed using MultiGauge 
software (v. 3.0, Fujifilm). In some cases, blots were reprobed with 
a second anti-protein citrulline antibody (1:500; MABN328EMD; 
Millipore; detection with horseradish peroxidase-labeled, goat 
anti-mouse IgM; 1:2500 in TBS-T; 31440, Thermo Scientific), 
with final overnight washing, to confirm the 6B3 immunoreactive 
features and increase the sensitivity of detection. No new signals 
were revealed by this approach.
The specificity of mAb 6B3 for detecting citrullinated proteins 
on western blots was confirmed by immunoneutralization, simi-
lar to the approach used for immunohistochemistry (see above), 
but involving solid-phase preadsorption (versus fluid phase) to 
accurately replicate the conditions of western blotting. In this 
case, the 6B3 antibody was reacted with a strip of nitrocellulose 
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(Protran® BA85, 0.45 μm pore size, binding capacity 80 μg/cm2; 
Sigma-Aldrich; cut into 1.4 cm × 3 cm pieces) to which either 
the citrullinated or native forms of fibrinogen had been bound. 
The amount of protein absorbed to the strip was 200 μl/200 μg of 
citrullinated human fibrinogen (400076, Cayman Chemical, Ann 
Arbor, MI, USA), or 200 μl/200 μg human fibrinogen (16088, 
Cayman Chemical) in TBS-T. The duration of the antibody 
absorption was 16 h at 4°C.
Protein Identifications
Immunoreactive signals of interest were mapped to corresponding 
features in Coomassie-stained gels. These features were excised 
and processed for identification through the ESMS-Basic Protein 
ID service using an Elite Orbitrap mass spectrometer (Thermo 
Scientific) by the W. M. Keck Mass Spectrometry and Proteomics 
Resource (W. M. Keck Foundation Biotechnology Resource 
Laboratory, New Haven, CT, USA). Analyses results were received 
through and tracked within the Yale Protein Expression Database 
(YPED) (Yale/NIDA Neuroproteomics Center, New Haven, CT, 
USA). Criteria for a positive identification included an expecta-
tion score <1.0E−65, a percent coverage >35.0%, and a pI and 
mw that were consistent with the fractionation data.
In Vitro Model of Protein citrullination Following 
TBi-induced excitotoxicity in astrocytes
An in vitro model of simulated TBI was established using normal 
human astrocytes (NHA CC-2565, Lonza, Allendale, NJ, USA) 
and treatment with the calcium ionophore, ionomycin (Free 
Acid, Streptomyces conglobatus, 407950, Calbiochem, Billerica, 
MA, USA), to simulate calcium excitotoxicity. Astrocytes 
were cultured to ~70% confluence in T-75 tissue culture flasks 
according to vendor instructions. Cells were washed with TBS 
(four times) and then treated for 4  h (37°C, 95% O2/5% CO2) 
with either ionomycin (10 μM; 10 ml TBS) or dimethyl sulfox-
ide vehicle (DMSO; 10  μl/10  ml TBS). Following incubation, 
protease inhibitors were added to the flasks (final concentration 
of 1×; Complete protease inhibitor mix; 10269700, Roche) and 
cells were harvested by scraping and centrifugation (800 × g, 4°C, 
10 min). Cells were extracted by vortexing into IEF denaturant 
(see Fluid-Phase Isoelectric Focusing) at a ratio of 1 part pellet 
to 4 parts buffer (v/v). Samples were clarified by centrifugation 
(15,000 × g, 4°C, 10 m). The resulting supernatant was processed 
by one-dimensional gel electrophoresis and immunoblotting 
as described above. Replicate immunoblots containing samples 
from three separate experiments each were probed with either 
anti-citrullinated protein (6B3) or anti-GFAP (1:3000, Z0334, 
DAKO, Carpinteria, CA, USA). Each primary antibody was 
paired with an appropriate secondary antibody (6B3: horserad-
ish peroxidase-labeled, goat anti-mouse IgG; 1:2500; 31430; 
Thermo Scientific; GFAP: horseradish peroxidase-labeled, goat 
anti-rabbit IgG; 1:3000; HAF008; R&D Systems) and blots were 
visualized by ECL.
statistical analysis
All animals in the study were scored using four brain sections per 
animal. Citrullination immunohistochemistry was quantified in 
the cortex using a previously developed scoring system (18), with 
a score of 0 reflecting the lowest amount of citrullination fluores-
cence intensity in a region and a score of 3 reflecting the greatest 
amount of fluorescence intensity (see Figure S1 in Supplementary 
Material). Four brain sections per animal were scored, and com-
parisons between groups were analyzed by ANOVA with a Tukey 
HSD post hoc test (IBM SPSS Statistics for Macintosh, Version 
22.0, Armonk, NY, USA: IBM Corp.). A value of p < 0.05 was 
considered significant.
results
Figure 1 presents the effects of CCI on the expression of citrul-
linated proteins in the rat cerebral cortex. Immunohistochemical 
analysis demonstrated that the basal level of protein citrullina-
tion as detected by labeling with mAB 6B3 was very low under 
control conditions. In contrast, CCI induced a marked increase 
in the immunolabeling of cells in the cortex. This up-regulation 
of protein citrullination was most pronounced in the vicinity of 
the lesion. The morphology of the affected cells was remarkably 
consistent, suggesting that the effects of CCI on protein citrullina-
tion were cell specific.
The specificity of mAb 6B3 labeling of citrullinated proteins in 
TBI brain was confirmed by immunoneutralization. As shown in 
Figure 2, preabsorption of the mAb 6B3 with citrullinated protein 
standard effectively eliminated the labeling of cells in the cerebral 
cortex and hippocampus of CCI brain. In this experiment, the 
active labeling condition utilized mAb 6B3 that had been exposed 
to the identical absorption procedures as the neutralized mAb 
6B3, except that the neutralizing proteins were not citrullinated 
under the control condition. Additionally, a secondary-only 
control was also conducted and further confirmed the specificity 
of the anti-citrullinated protein labeling (not shown).
The regional effects of CCI on protein citrullination are sum-
marized in Figure 3 and Figure S2 in Supplementary Material. 
CCI produced a marked increase in protein citrullination 
throughout the injured cortex, extending from lateral to the 
lesion site to regions of the cortex not directly impacted by CCI 
(Figure 3B). Scoring of this region revealed that male naïve rats 
(mean score: 0.06) and male CCI rats (mean score: 1.43) were 
significantly different, p <  0.001, and female naïve rats (mean 
score: 0.04) and female CCI rats (mean score: 1.35) were also 
significantly different, p < 0.001 (n = 11 male rats, CCI; n = 8 male 
rats, naïve control; n = 10 female rats, CCI; n = 7 female rats, naïve 
control) [F(3,32) = 31.05, p = 0.000, with post hoc Tukey HSD 
analyses considering injury and gender variables independently]. 
Similarly, immunolabeling of the injured ipsilateral hippocampal 
formation (Figure 3E) and external capsule (Figure 3H) showed 
similar increases in protein citrullination in these regions. To a 
lesser extent, protein citrullination was also observed in fibers 
extending ventrally from the lesion site toward the midline corpus 
callosum (not shown). Other brain regions, including the amyg-
dala and caudatoputamen, were completely negative for protein 
citrullination in these CCI animals. Furthermore, scoring of the 
cortex revealed that there was no gender difference observed in 
the regionalization or magnitude of protein citrullination fol-
lowing injury (CCI: p = 0.968; naïve: p = 0.999). In general, CCI 
appeared to have little effect on the status of protein citrullination 
 
FigUre 1 | injury upregulates the expression of citrullinated proteins in the cerebral cortex. Brain tissue was collected 5 days after CCI and evaluated for 
protein citrullination by anti-protein citrulline immunolabeling using mAB 6B3. The upper panels show immunolabeling in sections of control (left) and injured brain 
(right) (2× magnification). Lower panels show higher magnifications of cerebral cortex adjacent to the lesion site (right) or a comparable site in control cortex (left) 
(20× magnification). Data are representative of 15 control animals (8 males and 7 females) and 21 CCI animals (11 males and 10 females). No gender-based 
differences were observed. PB-cit, protein-bound citrulline.
FigUre 2 | specificity of anti-protein citrulline immunolabeling by mab 6B3. (a,B) show immunofluorescent signals from mAb 6B3 anti-protein citrulline 
labeling of the injured cerebral cortex (a) and ipsilateral hippocampus (B). (c,D) shows immunolabeling of equivalent sections with mAb 6B3 that was preadsorbed 
with citrullinated protein standards. The control and immunoneutralized preparations of mAb 6B3 were treated identically, with the exception of the presence or 
absence of neutralizing citrullinated proteins. Data are representative of two independent experiments. Scale bar: 200 μm.
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in contralateral brain structures, with the exception of the dorsal 
hippocampus, where ~20% of injured animals (4 of 21) displayed an 
intense labeling of unusually large and rounded cells (Figure 3F). 
Finally, 6B3 immunolabeling was uniformly low across all regions 
studied in control male and female animals (Figures 3A,D,G).
Dual immunofluorescence revealed astrocytes to be the 
principal cell type in which protein citrullination was affected by 
CCI. Figure  4 shows that anti-citrulline labeling in the cortex 
and external capsule was predominantly co-localized with 
GFAP. Similar observations were made in other affected brain 
regions. The findings presented in Figure 5 further confirm that 
CCI-induced protein citrullination was not significantly associ-
ated with neurons (NeuN), microglia/macrophages (Iba1), or 
oligodendrocytes (MBP) in the cortex. Citrullination was also not 
significantly associated with these cell types in any other brain 
regions investigated (not shown). It should be noted that the lack 
of co-localization of protein citrullination with NeuN immunore-
activity might reflect diminished NeuN expression following TBI, 
rather than a lack of citrullinated proteins within neurons. The 
distinctive profile of CCI-induced protein citrullination in the 
ipsilateral and contralateral hippocampus is shown in Figure 6. 
As noted above, increased anti-citrullinated protein labeling 
was clearly evident in the ipsilateral hippocampus of all animals 
studied (Figure 6A), and this labeling co-localized with GFAP 
labeling (Figures  6B,C). In addition, in ~20% of injured ani-
mals, the contralateral hippocampus also displayed intense 6B3 
labeling (Figure 6D) that co-localized with GFAP labeling. The 
co-labeled cells were morphologically distinct from traditional 
stellate astrocytes, displaying a rounded, branchless appearance 
consistent with that of a macrophage (Figures 6E–G).
Figure 7 demonstrates the specificity of the 6B3 antibody for 
detecting citrullinated proteins in a western blot format. Shown 
on the left is the Coomassie staining for human fibrinogen (Fib) 
and the same preparation of fibrinogen that was enzymatically 
citrullinated by reaction with PAD4 (C-Fib). The protein staining 
shows that the characteristic profile of purified human fibrino-
gen is modestly affected by reaction with PAD4. Presented on 
the right are immunoblots showing the reactivity of mAb 6B3 
with the citrullinated fibrinogen preparation (Active/C-Fib) and 
the elimination of this reactivity by preabsorption of 6B3 with 
FigUre 3 | increased protein citrullination in the cerebral cortex, hippocampus and external capsule following cci. Anti-protein citrulline 
immunolabeling by mAb 6B3 is shown for the control brain regions (a,D,g), regions ipsilateral to the lesion (B,e,h), and regions contralateral to the lesion (c,F,i). 
Structures represented are the cerebral cortex (a–c), hippocampus (D–F), and external capsule (g–i). Data are representative of 15 control animals (8 males and 7 
females) and 21 CCI animals (11 males and 10 females). No gender-based differences were observed. Scale bar: 200 μm.
FigUre 4 | localization of cci-induced protein citrullination to astrocytes. Panels on the left show the co-localization of mAb 6B3 labeling with anti-GFAP 
labeling in the external capsule. Panels on the right show the co-localization of mAb 6B3 labeling with anti-GFAP labeling in the cerebral cortex. Data are 
representative of 15 control animals (8 males and 7 females) and 21 CCI animals (11 males and 10 females). No gender-based differences were observed. Scale 
bar: 200 μm. PB-cit, protein-bound citrulline.
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citrullinated fibrinogen prior to blotting (Neutralized/C-Fib). 
There was no reactivity of mAb 6B3 with fibrinogen that had not 
been citrullinated by PAD4 treatment (Active/Fib).
Proteomic analysis revealed that the effects of CCI on protein 
citrullination were specific to a discrete subset of proteins mak-
ing up the entire brain proteome, and further, that the proteins 
involved are primarily associated with cytoskeletal structure and 
metabolic processes (Figure 8). Shown in the upper left panel are 
the proteomes of control and injured cerebral cortex fractionated 
by fluid-phase isoelectric focusing. Each pair of lanes, control 
(C) and CCI (I), show the proteins present in the four different 
pI partitions. As visualized by Commassie staining, CCI did not 
appreciably affect the general pattern of protein staining across 
the four pI fractions. In contrast, the pattern of protein citrul-
lination was dramatically impacted by CCI (upper right panel). 
Consistent with immunohistochemistry findings (Figures  2 
and 3), little protein citrullination was observed in control cortex 
(C), whereas CCI (I) resulted in the intense labeling of a distinc-
tive subset of the fractionated proteins. The immunoreactive 
signals of the western blot were mapped to Commassie features 
of the protein gel, and proteins were identified by peptide mass 
fingerprinting and tandem mass spectrometry. The proteins iden-
tified are presented in the lower panel of Figure 8. These proteins 
are functionally grouped as cytoskeletal components (including 
dynamin-1, GFAP, and several forms of tubulin); those involved 
in metabolic processes (including peroxiredoxin-1, dihydropy-
rimidinase-related protein 2, and creatine kinase B-type); and 
proteins involved in cell–cell signaling and synaptic transmission 
(synapsin-2, syntaxin-binding protein 1, and amphyiphysin). It 
should be noted that these functional groups of affected pro-
teins – cytoskeletal components, metabolic proteins, and proteins 
involved in cell–cell signaling  –  may have been preferentially 
FigUre 5 | cci did not affect the status of protein citrullination in neurons, microglia or oligodendrocytes. Sections of cerebral cortex ipsilateral to CCI 
were probed with mAb 6B3 to label protein-bound citrulline (PB-cit) (upper panels) and either anti-NeuN, Iba1, or MBP to label neurons, microglia, or 
oligodendrocytes, respectively (middle panels). The merge of the two signals is presented in the lower panels. Data are representative of eight separate experiments. 
Scale bar = 200 μm.
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identified as citrullinated due to their relatively high abundance. 
These abundant protein types may be more easily identifiable 
through proteomic analyses than less abundant proteins, which 
may also be citrullinated but not easily identified. In this regard, 
however, only a small proportion of the very high abundance pro-
teins were identified as being citrullinated, indicating a notable 
degree of specificity in the citrullination response.
Analysis of the mass spectra data set with a variable modifica-
tion search for the citrullination of arginine residues revealed 
many sites of citrullination on arginine residues with Mascot 
score corresponding to p < 0.05. Table 1 lists the various pro-
teins and corresponding sequences where arginines were shown 
to be citrullinated. The LC MS/MS approach did not identify 
all the proteins that were detected through the use of the 6B3 
anti-citrullinated protein antibody as containing citrullinated 
residues. Some possible explanations for this include, but are not 
limited to (1) overlapping of ion peaks due to similarity in mass 
with deamidation of Arg, (2) low abundance of citrullination 
modification to below the detection limit of the LC MS/MS tech-
nique but not western blot, (3) poor ionization of a citrullinated 
peptide, (4) poor fragmentation of a citrullinated peptide, and (5) 
non-specificity detection of the proteins by western blot.
To further investigate the cellular mechanisms of injury-
induced protein citrullination, a model of simulated TBI was 
established. In this model, normal human astrocytes (obtained 
commercially) were incubated in control medium or in medium 
containing the calcium ionophore, ionomycin, to induce calcium 
excitotoxicity. Figure 9 shows the results of three separate experi-
ments investigating the effects of ionomycin treatment on the 
proteolytic processing of GFAP (left panel) and the generation of 
citrullinated proteins (right panel). The data show that treatment 
with ionomycin consistently activated the proteolytic processing 
of intact GFAP (left panel; blue arrows) to produce a distinctive 
pattern of breakdown products. Probing with mAb 6B3 indicated 
that one of the GFAP breakdown products is preferentially citrul-
linated (right panel; orange arrow) in response to simulated TBI. 
In addition, several other protein features appeared to be heavily 
citrullinated in response to ionomycin treatment. The identity of 
these signals remains to be determined.
Discussion
Protein citrullination is a calcium-dependent protein modifica-
tion that has been largely studied in the context of autoimmune 
FigUre 6 | effects of cci on protein citrullination in gFaP-positive cells of the ipsilateral and contralateral hippocampus. Co-localization of anti-protein 
citrulline and anti-GFAP labeling in astrocytes of the ipsilateral hippocampus is depicted in the pairs of panels presented on the left (a–c). (D) Shows the distinctive 
anti-citrullinated protein immunolabeling of large, rounded cells observed in the contralateral hippocampus of ~20% of CCI animals (4 of 21). While these cells 
lacked the classical stellate morphology of astrocytes, the anti-citrullinated protein labeling co-localized with GFAP immunolabeling (e–g). PB-cit, protein-bound 
citrulline.
FigUre 7 | specificity of anti-protein citrulline mab 6B3 detection for 
western blotting. Displayed on the left are two Coomassie-stained profiles 
showing the protein composition of native fibrinogen (Fib) and citrullinated 
fibrinogen (C-Fib). The western blot (right) shows three immunoblots in which 
citrullinated fibrinogen was probed with active mAb 6B3 (Active/C-Fib; left 
lane); citrullinated fibrinogen was probed with immunoneutralized mAb 6B3 
(Neutralized/C-Fib; middle lane); and native fibrinogen was probed with active 
mAb 6B3 (Active/Fib; right lane).
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disorders, particularly rheumatoid arthritis. Abnormal protein 
citrullination in rheumatoid arthritis results in the generation 
of antigenic epitopes that become targeted by the adaptive 
immune system (16, 24). Protein citrullination is also found to 
be abnormal in several neurodegenerative disorders, includ-
ing MS and Alzheimer’s disease, suggesting that citrullinated 
proteins may also serve as antigenic targets in these conditions, 
and thereby contribute to long-term pathogenesis. To date, how-
ever, little research has examined the effects of TBI on protein 
citrullination, where an acute mechanical injury can lead to 
progressive and sustained neuropathology. Currently, there are 
no data regarding the identity of specific proteins affected by 
citrullination following TBI, or information on the susceptibil-
ity of different brain regions or cell types to this modification 
following injury.
The constellation of dysfunctions resulting from TBI is often 
complex and dynamic, involving pathology caused by acute tissue 
damage and interactions amongst the ongoing changes caused 
by ischemia, hypoxia, excitotoxicity, and elevated intracranial 
pressure (1). A hallmark of acute TBI pathophysiology, however, 
is intracellular calcium overload (25). This shift in ionic balance 
is excitotoxic, activating a number of damaging intracellular 
cascades, including lipid peroxidation, proteolysis, free radical 
generation (2), and the activation of pro-apoptotic genes (1) with 
the loss of dendritic spines. Elevated intracellular calcium is an 
essential condition for the activation of PAD enzymes, which 
catalyze the conversion of intrapeptidyl arginine residues to 
citrulline residues (26).
PAD enzymes exist as several isoforms, two of which are 
found in neural tissue: PAD2 (20, 27, 28) and PAD4 (29). In 
humans, PAD2 is largely localized to astrocytes, while PAD4 
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FigUre 8 | identification of proteins that are citrullinated in response to cci. Extracts of control (C) and injured (I) cerebral cortex were fractionated by 
fluid-phase isoelectric focusing into defined pH ranges (shown at top) and then further resolved according to molecular weight using one-dimensional gel 
electrophoresis. Proteins were then transferred to nitrocellulose membranes and probed for protein-bound citrulline (see “Materials and Methods”) (right panel, 
“Western blot”). Gels run in parallel were visualized with Coomassie (left panel). Sixteen features showing increased citrullination in response to CCI (black numbered 
boxes, right panel) were mapped to corresponding Coomassie features (red numbered boxes, left panel) and identified by peptide mass finger printing and tandem 
mass spectrometry. Proteins identified are listed in the lower panel. Analysis of the mass spectra data set with a variable modification search for the citrullination of 
arginine residues revealed several proteins with sites of citrullination on arginine residues with Mascot score corresponding to p < 0.05 (Cit Pep). Several of these 
proteins (Prev Report) are also citrullinated in other pathologies, including ALDOA, ALDOC, GFAP, PRDX1, COF1, ENOA, ENOG, MBP, and tubulin (beta) in prion 
disease (20, 21); GFAP and MBP in Alzheimer’s disease and multiple sclerosis (16); ENOA in rheumatoid arthritis (22); and GRP78 in Type I diabetes (23). Images are 
representative of six independent experiments. A total of n = 4 CCI and n = 4 control animals were examined.
is exclusively expressed in neurons (29). Moreover, PAD2 is 
localized to reactive astrocytes in the brains of mice affected by 
a prion disorder, scrapie, where its enzymatic activity is nearly 
double that of healthy mice (20). Research on the etiology of 
MS has suggested that PAD2 contributes to the pathology of 
demyelination, where its activity is thought to destabilize myelin 
sheath structure (17).
The present investigation in rats indicates that TBI-induced 
protein citrullination is selectively localized to astrocytes. This 
finding is consistent with the understanding that following 
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ischemia, astrocytes exhibit a dramatic rise in intracellular cal-
cium due to a rapid influx of extracellular calcium through dys-
functional membrane channels as well as the release of calcium 
from intracellular stores (25). While influxes in intracellular 
calcium are also found in neurons following mechanical injury, 
TaBle 1 | Proteins identified to be citrullinated in response to TBi.
Protein sequence Mascot score Function
Alpha-actinin-1 K.LRKDDPLTNLNT AFDVAER.Y 46.99 F-actin cross-linking protein which is thought to anchor actin to a variety of 
intracellular structures. http://www.uniprot.org/uniprot/Q9Z1P2
Amphiphysin R.LQRELR.G 16.38 Involved in regulation of synaptic vesicle endocytosis and tumor suppression 
inhibiting malignant cell transformation. http://www.uniprot.org/uniprot/O08839
Creatine kinase 
B-type
K.LLIEMEQRLEQG QPIDDLMPAQK. 42.46 Creatine kinase isoenzymes play a central role in energy metabolism.  
http://www.uniprot.org/uniprot/P07335
Drebrin R.LKDQSIFGDQRD EEEESQMK.K 
K.KALDARLR.F
45.82 29.54 Drebrins are thought to function in cell migration, extension of neuronal 
processes and plasticity of dendrites. http://www.uniprot.org/uniprot/Q16643
Dynamin-1 R.SGQASPSRPESPR PPFDL. 17.90 Mediates clathrin-endocytosis and other vesicular trafficking processes.  
http://www.uniprot.org/uniprot/A0A0A0MY51
Fructose-
bisphosphate 
aldolase A
K.RALANSLACQGK.Y 10.24 Functions in glycolysis and gluconeogenesis.  
http://www.uniprot.org/uniprot/P05065
Heat shock  
cognate 71 kDa
K.VEIIANDQGNRTT PSYVAFTDTER.L 43.26 Acts as a repressor of transcriptional activation. Chaperone.  
http://www.uniprot.org/uniprot/P63018
Moesin K.ERQEAEEAKEAL LQASR.D 21.64 Connects cytoskeletons to membranes.  
http://www.uniprot.org/uniprot/P26038
Myelin basic  
protein
R.FFSGDRGAPK.R K.GRGLSLSR.F 60.90 11.7 A highly abundant protein in the myelin membrane that surrounds neurons. 
http://www.uniprot.org/uniprot/P02688
NADH-ubiquinone 
oxidoreductase 
75kDa subunit
R.IASQVAALDLGY KPGVEAIRK.N 
K.VALIGSPVDLTY RYDHLGDSPK.I
26.71 24.23 Core subunit of the mitochondrial membrane respiratory chain NADH 
dehydrogenase (Complex I). http://www.uniprot.org/uniprot/Q91VD9
Septin-9 R.RVETPASKAPEG SAMPVTDAAPK.R 13.24 Filament-forming cytoskeletal GTPase that is thought to play a role in 
cytokinesis. http://www.uniprot.org/uniprot/Q9QZR6
Synapsin-1 R.PVAGGPGAPPAA RPPASPSPQR.Q 38.25 A phosphoprotein of synaptic vesicles, thought to function in the regulation of 
neurotransmitter release. http://www.uniprot.org/uniprot/P09951
Synapsin-2 K.YDIRVQK.I 19.95 A phosphoprotein of synaptic vesicles, thought to function in the regulation of 
neurotransmitter release. May play a specific role in noradrenaline secretion by 
sympathetic neurons. http://www.uniprot.org/uniprot/Q63537
Analysis of the mass spectra data set with a variable modification search for the citrullination of arginine residues revealed many sites of citrullination on arginine residues with 
Mascot score corresponding to p < 0.05. The LC MS/MS approach did not identify all the proteins that were detected through the use of the 6B3 anti-citrullinated protein antibody 
as containing citrullinated residues. Some possible explanations for this include, but are not limited to (1) overlapping of ion peaks due to similarity in mass with deamidation of Arg, 
(2) low abundance of citrullination modification to below the detection limit of the LC MS/MS technique but not western blot, (3) poor ionization of a citrullinated peptide, (4) poor 
fragmentation of a citrullinated peptide, and (5) non-specificity detection of the proteins by western blot.
Significance of red font: Arginine (R).
this rise is far less profound than that observed in astrocytes (30). 
Furthermore, astrocytes selectively display long-term defects in 
calcium signaling following TBI (30) and ultimately, astrocytic 
death precedes that of neurons in rat models of TBI (25). Related 
findings involving hypoxia confirm that astroglial injury is due 
FigUre 9 | simulated brain injury in normal human astrocytes reveals a spectrum of gFaP breakdown products and the hyper-citrullination of one 
gFaP species. Normal human astrocytes were treated with ionomycin (10 μM; 4 h) and analyzed for GFAP (left panel) and protein-bound citrulline immunoreactivity 
(right panel) by western blot. The results of three independent experiments (A–C) are presented, showing the immunoreactivity in extracts prepared from untreated 
control cells (Control) and cells treated with ionomycin (+Iono). The blue arrows indicate intact GFAP, while the orange arrows indicate the hyper-citrullinated GFAP 
breakdown product.
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to massive calcium influxes and resulting excitotoxicity (26). 
Models of TBI illuminate the biologic importance of astrocytes in 
brain injury, serving a protective role by shielding neurons from 
damage due to oxygen deprivation (31), glutamate neurotoxicity, 
and calcium excitotoxicity (32). It has been proposed that the 
intracellular rise of calcium within astrocytes is directly linked 
to their neuroprotective effects on neurons, most likely due to 
their ability to sequester large amounts of calcium, and thus 
stabilize the ionic environment for neurons (33). Our finding that 
protein citrullination is limited to astrocytes is consistent with 
this proposal.
Present results indicate that the up-regulation of protein cit-
rullination induced by TBI occurs in astrocytes that are located 
in the cerebral cortex, external capsule, and hippocampus. In 
contrast, the status of protein citrullination in other brain regions 
(such as the amygdala and caudate putamen) and cell types was 
not appreciably altered by TBI. The mechanistic basis for this 
observation may relate to the up-regulation of voltage-gated, 
class C L-type Ca2+ channels that are selectively expressed in 
astrocytes and are particularly sensitive to activation by injury 
in the regions reported here (34). The finding that nimodipine, 
an L-type calcium channel blocker, protects against excitotoxic 
damage in cultured astrocytes supports this proposal (35). These 
findings correspond to a model of calcium excitotoxicity-induced 
citrullination. The selective citrullination of astrocytes in these 
particular regions may correspond to long-term dysfunctions 
associated with TBI, including learning and memory deficits 
associated with progressive hippocampal atrophy (1). However, 
it is possible that citrullination may occur in other cell types at 
different time points following TBI, and future work is needed to 
address this possibility. Furthermore, a subset of astrocytes – in 
particular, perivascular astrocytes with end-feet contacting ves-
sels, as well as the glia limitans underlying the pia mater – were 
particularly rich in citrullianted proteins. This may reflect a 
functional relevance of citrullinated proteins and their proxim-
ity to the blood–brain barrier, indicating a potential exposure 
of these modified molecules to the immune system, where 
citrullinated epitopes may stimulate the production of targeted 
immunogenicity.
Our investigation suggested that patterns of protein citrullina-
tion following TBI were similar between male and female rats. 
This finding is in contrast to our previous observations concern-
ing the effects of TBI on protein carbonylation. Following injury, 
male rats showed far greater response in protein carbonylation as 
compared to female rats (18). Protein carbonylation is a reflection 
of oxidative stress (36), whereas citrullination is a marker of cal-
cium influx (22, 37). Accordingly, the gender difference observed 
in carbonylation may be due to the protective antioxidant effects 
of ovarian steroids (38), whereas a similar mechanism does not 
appear to exist in the case of citrullination. The extent to which 
these protein modifications contribute to gender differences in 
TBI complications and mortality (39, 40) remains to be deter-
mined. It should be noted that the present experimental design 
focused on only one time point post-TBI (5 days), and as such, 
it is possible that gender differences in post-injury citrullination 
may be evident at other time points.
The present investigation has identified 37 proteins as a 
very small subset of the entire brain proteome that is possibly 
citrullinated in response to TBI. This potential selectivity in 
protein citrullination indicates that the mechanism involved 
maintains a high degree of specificity. Furthermore, several 
of the proteins identified here are reported to be citrullinated 
in neurodegenerative diseases, and thus may play causative 
roles in neuropathology. Specifically, citrullinated GFAP is a 
characteristic feature in MS and Alzheimer’s disease (11, 16, 41, 
42), and MBP, a major component of myelin sheath structure, 
is profoundly over-citrullinated in MS (42, 43). Similarly, GFAP, 
tubulin, peroxiredoxin 1, cofilin-1, and alpha/gamma enolase are 
selectively citrullinated in prion disease (20). Therefore, the link 
between abnormal protein citrullination and neurological disease 
appears strong. It should be noted that the 37 proteins identified 
as targets for TBI-induced citrullination were derived from the 
analysis of only 16 gel features. Accordingly, not all of the proteins 
identified in a single feature are necessarily citrullinated, and may 
have resulted from the analysis due to their co-purification with 
another citrullinated species. Nevertheless, the high correlation 
that exists between the specific proteins potentially identified 
here and their reported citrullination in various disease states is 
consistent with the proposal that these proteins are indeed targets 
for citrullination following TBI.
A possible mechanism by which abnormal protein citrul-
lination contributes to neurological disease could involve the 
adaptive immune system. A significant proportion of the pro-
teins identified here are also recognized as autoantigens, in both 
neurological and autoimmune-related disorders. For example, 
MBP is the signature citrullinated autoantigen of MS (43, 44). 
Autoantibodies targeting amphiphysin are associated with sev-
eral neurological disorders, including sensory neuronopathy and 
encephalopathy (45). Additionally, dihydropyrimidinase-related 
protein 2 (CRMP2) is autoantigenic in autoimmune retinopathy 
(46). Finally, alpha enolase has been identified as a citrullinated 
autoantigen in rheumatoid arthritis (22), while citrullinated 
78  kDa glucose-regulated protein is an autoantigen within the 
pancreatic beta-cells in Type 1 diabetes (23). Collectively, these 
findings support the proposal that injury-induced protein cit-
rullination may generate immunological epitopes that become 
targets of the adaptive immune system. This process may serve 
as an underlying basis for chronic and progressive neurological 
disorders.
Finally, this report presents the development of an in  vitro 
model for simulating TBI in a controlled and cell-specific man-
ner. Shown here in normal human astrocytes are the effects of 
calcium excitotoxicity, a hallmark condition of TBI, on the 
hyper-citrullination of GFAP. Moreover, the findings confirm the 
proteolytic processing of GFAP to a series of breakdown products 
that are consistent with those reported by others using in vitro 
models of TBI (47, 48). Interestingly, our investigation showed 
that one of these breakdown products is heavily citrullinated, and 
thus may serve as the antigen for the development of the anti-
GFAP autoantibodies recently reported in TBI (49). Accordingly, 
the application to this and other models for simulated TBI may 
provide novel insights into consequences and mechanisms of 
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TBI, and also identify informative biomarkers for assessing brain 
injury.
In conclusion, the present findings indicate that TBI may 
dramatically up-regulate protein citrullination within astrocytes 
in specific brain regions. Additionally, this modification may 
affect only a subset of the neural proteome, primarily affecting 
proteins involved in cytoskeletal structure, metabolic processes, 
and cell–cell signaling. A large proportion of these proteins have 
been identified as citrullinated in other pathologies, including 
MS, Alzheimer’s disease, and rheumatoid arthritis, indicat-
ing a potential role for this protein modification in ongoing 
pathological processes. Interestingly, gender does not affect 
the degree or distribution of this modification in neural tissue, 
in contrast to previous observations involving TBI-induced 
protein carbonylation. Accordingly, gender differences in the 
CNS response to TBI may not involve differential responses in 
protein citrullination. Finally, the work presented here examined 
protein citrullination only at 5 days following injury. According 
future work is needed to address the presence of citrullination 
following TBI in an extended time course to investigate the 
long-lasting effects of TBI on the status of protein citrullination 
in the central nervous system. In summary, this research indi-
cates that abnormal protein citrullination is a possible feature of 
TBI that may contribute to ongoing pathological mechanisms 
following acute injury, potentially including aspects of autoim-
mune dysfunction.
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